In the EMILIA study, T-DM1 exhibited improved survival for the second-line treatment of metastatic HER2-positive breast cancer compared to the existing standard therapy, capecitabine with lapatinib, a HER2 tyrosine kinase inhibitor [23]. The gene discussed is ERBB2; the disease is breast cancer.